Novo Nordisk has generously offered to make a donation to Diabetes Hands Foundation (the nonprofit that runs TuDiabetes) for every pledge made on www.DrivetheSwitch.com, up to $10,000.
Here are the details about the program, announced earlier today…
Novo Nordisk and Charlie Kimball Team Up to Challenge Diabetes Patients to Re-think How They Take Insulin
St. Petersburg, FL (March 24, 2011) – Novo Nordisk, a world leader in diabetes care, is partnering with 2011 IZOD IndyCar Series driver Charlie Kimball to launch the educational program, Drive the Switch, encouraging diabetes patients who use insulin and caregivers to pledge to talk to their healthcare professional about options for insulin delivery, like the prefilled insulin pen device. Nearly 90 years since the discovery of insulin, Americans still have not embraced more recent options in insulin delivery. In fact, the United States lags behind the rest of the world, with less than 20 percent of people with diabetes using a prefilled insulin pen to inject their insulin . In other parts of the world, pen usage is as high as 85 percent, according to a 2008 survey .
For each person who pledges, Novo Nordisk will make a donation to Diabetes Hands Foundation up to a total of $10,000. Patients and caregivers will be able to pledge online by visiting www.DrivetheSwitch.com. Website visitors will also be able to see how many people have pledged, identify locations where Charlie and his car will appear throughout the 2011 season and learn about Novo Nordisk treatment options like the prefilled insulin device Levemir® (insulin detemir [rDNA origin] injection) FlexPen®.
“We are excited to be partnering with Charlie on this initiative since his story exemplifies how today’s insulin delivery devices can help patients manage their diabetes,” said Camille Lee, Vice President, Diabetes Marketing. “With devices like FlexPen®, the #1 selling prefilled insulin pen in the world, people with diabetes now have the ability to take their insulin with them on-the-go.”
Diagnosed with diabetes in 2007, Charlie Kimball uses Levemir® (insulin detemir [rDNA origin] injection) FlexPen® as part of his treatment regimen. Kimball also uses NovoLog® (insulin aspart [rDNA origin] injection) to help manage his diabetes. As part of his race preparation, Kimball monitors his blood sugar closely before, during and after each race.
“I’m living proof that today’s insulin delivery device options can help you successfully manage your diabetes in the most challenging circumstances,” said Kimball, who drives the No. 83 Levemir® and NovoLog® FlexPen® Honda Dallara car for Novo Nordisk Chip Ganassi Racing. “I hope to serve as a role model for people living with diabetes to let them know that with the right tools, diabetes doesn’t have to stop you from pursuing your dreams.”
Novo Nordisk offers a comprehensive line of insulin analog products that are available for use with the FlexPen®, including Levemir® (insulin detemir [rDNA origin] injection) FlexPen®, NovoLog® [insulin aspart (rDNA origin) injection] FlexPen®, and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) FlexPen®. FlexPen® is covered on more than 90 percent of insurance plans.
To learn more about the program and pledge to speak to your healthcare professional, visit www.DrivetheSwitch.com. You can also follow Kimball and his work with Novo Nordisk on Twitter - @racewithinsulin.